Orchard was founded in 2015—but their roots run deeper, going back to some of the first research and clinical development involving hematopoietic stem cell, or HSC, gene therapy. Orchard’s team has played a central role in the evolution of this technology from a promising idea to a potentially life-transforming reality. Today, they carry forward company’s history of visionary science to imagine new possibilities for people and families affected by genetic and other severe diseases.
In 2018, after acquiring GSK’s rare disease gene therapy portfolio, Orchard is advancing a pipeline spanning pre-clinical, clinical, and commercial stage HSC gene therapies designed to address serious diseases.
Our task was to deliver the company’s new HQ & R&D facility at the upcoming research hub of Hammersmith in London. The works involved compliant (CL2) laboratories, and associated offices.
Skills & Results
Orchard Therapeutics were looking to expand their research and development facility in London. After winning the project against a competitor, the Bulb team designed and delivered this facility occupying 75% of the 3rd floor space at 245, Hammersmith Road.
The fit out involved splitting the floor plate into a lab to office ratio of approx. 60:40. The laboratory areas involved general purpose labs, research labs and a production room providing space for a bigger bioreactor. The detailed lab design was carried out following a series of workshops with the scientific personnel working in each lab. The lab benching and room configurations follow the specific process flow undertaken in each room.
Shared facilities included glass wash, cryostorage (LN2/Freezers), consumables and waste storage.
Laboratory services include appropriate ventilation, vinyl flooring, technical lighting, vulcathene drainage, industrial gases distribution and monitoring.
The office space includes an impressive reception, modern open office, several meeting rooms, a large training room that can be opened for townhall meetings and a spacious breakout area.